Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease.  Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC Medical Group in Columbia, South Carolina presented preliminary results from the company’s clinical development program at the recent Eastern Vascular Society Meeting in Pittsburg, Pennsylvania.

The presentation included outcomes of two cohorts – a non-randomized Phase 2 (n=30; 2 international sites, 2 surgeons) and the open label subset (OL; n=26; 20 U.S. sites, 26 surgeons) of the ACCESS study, an ongoing, randomized, controlled, multicenter US Phase 3 trial.  For the composite study group of 56 patients:

  • 78% and 73% of AVF were suitable for dialysis at 6 and 12 months respectively
  • Median time to first dialysis was 49 days
  • 12-month secondary patency was 73%
  • No product related serious adverse events were reported

These outcomes provide a strong efficacy signal.  Enrollment in the ACCESS study was completed in August 2019 and included 243 patients.  The 6-month primary endpoint (Fistula Suitability for Dialysis at 6 Months) results are expected to be announced in the second quarter of 2020.

Dr. Clair commented “these preliminary results are very encouraging and suggest that intraoperative perivascular sirolimus may improve AV fistula outcomes in dialysis patients.  We look forward to seeing the primary endpoint results from the randomized cohort.”  Maria DeVita, MD, Chief of Nephrology at Lenox Hill Hospital in New York and medical monitor for the study added “Vascular access failures in hemodialysis patients is an important unmet medical need.  I commend Vascular Therapies for developing this therapy and would like to thank the patients, nephrologists, surgeons and clinical coordinators for their participation in these important studies.”

 

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles